1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is the most common form of age-related dementia in the elderly. The increase of the average age of the population is causing a significant rise in the number of people afflicted with this devastating disease, and it is predicted that the incidence of AD will approximately triplicate by 2040 \[[@B1]\] if more effective therapeutic strategies are not made available. In order to develop better therapeutic approaches, the molecular pathways leading to the pathological alterations of the disease must be fully understood.

Major neuropathological and neurochemical hallmarks of AD traditionally included the extracellular accumulation of amyloid-*β* peptide (A*β*) in brain senile plaques, the intracellular formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated Tau protein, the loss of synapses at specific brain sites, and the degeneration of cholinergic neurons from the basal forebrain \[[@B2]\]. The original amyloid cascade hypothesis had proposed that the key event in AD development is the extracellular accumulation of insoluble, fibrillar A*β* \[[@B3]--[@B5]\]. This "extracellular insoluble A*β* toxicity" hypothesis was later modified to acknowledge the role of soluble A*β* oligomers as pathogenic agents. Only more recently the importance of intraneuronal A*β* accumulation in the pathogenesis of AD has been recognized, despite the fact that the original reports showing A*β* accumulation inside neurons are dated more than 20 years ago. The "intraneuronal A*β* hypothesis" does not argue against a role for extracellular A*β* but complements the traditional amyloid cascade hypothesis \[[@B6]--[@B8]\].

The intraneuronal pool of A*β* originates from APP cleavage within neurons and from A*β* internalization from the extracellular milieu. Here we focus on the mechanisms that mediate A*β* internalization in neurons and glia, and we discuss the consequences of A*β* uptake by brain cells.

2. Intraneuronal A*β* {#sec2}
=====================

Evidence from several immunohistochemical studies suggested the accumulation of intraneuronal A*β* in AD. Yet, the acceptance of this concept was hampered by the fact that in many studies, antibodies that could not distinguish between APP and A*β* inside the neurons were used. This problem and other experimental issues have been addressed in detail elsewhere \[[@B9]--[@B11]\]. Despite these initial technical complications, several studies using antibodies specific for A*β*~40~ and A*β*~42~ have confirmed the presence of intraneuronal A*β* and suggested a pathophysiological role for this A*β* pool \[[@B12]--[@B14]\]. In the past few years several excellent reviews have discussed the evidence available on accumulation of intracellular A*β* in brains of AD patients and animal models of AD and its impacts on pathogenesis of AD, synaptic impairment, and neuronal loss \[[@B6], [@B9], [@B11], [@B15]--[@B17]\]. Here we just mention the most salient aspects of intracellular A*β* accumulation without reviewing the evidence exhaustively.

Intraneuronal accumulation of A*β* is one of the earliest pathological events in humans and in animal models of AD. Intraneuronal A*β*~42~ immunoreactivity precedes both NFT and A*β* plaque deposition \[[@B12], [@B13]\], and in the triple transgenic mouse model, Long-Term Potentiation (LTP) abnormalities and cognitive dysfunctions correlate with the appearance of intraneuronal A*β*, prior to the occurrence of plaques or tangles \[[@B18], [@B19]\]. Moreover, when A*β* is removed by immunotherapy, the intracellular pool of A*β* reappears before tau pathology \[[@B20]\]. Importantly, A*β* accumulation within neurons precedes neurodegeneration in nearly all the animal models in which intracellular A*β* and neuronal loss have been reported, and all models in which intracellular accumulation of A*β* was examined and was present showed synaptic dysfunction \[[@B21]\]. Studies in cultured cells also showed accumulation of intracellular A*β* \[[@B22]--[@B24]\].

The observation that cortical neurons that accumulate A*β*~42~ in brains of AD and Down syndrome patients are apoptotic \[[@B25], [@B26]\] and that microinjections of A*β*~42~ or cDNA-expressing cytosolic A*β*~42~ rapidly induce cell death of primary human neurons \[[@B27]\] indicated the importance of intracellular A*β* in neuronal death. In support of this notion, generation of transgenic mice harboring constructs that target A*β* either extracellularly or intracellularly has demonstrated that only intracellular A*β*-producing transgenic mice developed neurodegeneration \[[@B28]\]. Furthermore, a recent quadruple-mutant mouse has shown neuronal loss in association with intracellular accumulation of A*β* \[[@B29]\]. There is also mounting evidence that intracellular A*β* accumulation is associated with neuritic and synaptic pathology \[[@B24], [@B30], [@B31]\] and with alterations of synaptic proteins \[[@B32]\]. Besides, the internalization of A*β* antibodies reduced intraneuronal A*β* and protected synapses \[[@B33]\] as well as reversed cognitive impairment \[[@B19]\].

With respect to the specific form of A*β* that accumulates intracellularly, the use of C-terminal-specific antibodies against A*β*~40~ and A*β*~42~ in immunocytochemical studies of human brains with AD pathology, indicated that it is A*β*~42~ the peptide present within neurons \[[@B12], [@B13], [@B34]--[@B38]\]. Furthermore, using laser capture microdissection of pyramidal neurons in AD brains, Aoki and collaborators showed increased A*β*~42~ levels and elevated A*β*~42~/A*β*~40~ ratio in neurons from sporadic as well as from familial cases of AD, whereas A*β*~40~ levels remained unchanged \[[@B39]\].

An interesting development of the "intracellular A*β*" cascade is the possibility that A*β* plaques would originate from death and destruction of neurons that contained elevated amounts of A*β* \[[@B13], [@B40], [@B41]\]. Indeed, the release of A*β* from intracellular stores by dying cells seems responsible for the reduction or loss of intraneuronal A*β*~42~ immunoreactivity in areas of plaque formation \[[@B12]\]. Recently, a model was presented in which internalized A*β* starts fibrillization in the multivesicular bodies (MVBs) upon spontaneous nucleation or in the presence of fibril seeds, thus penetrating the vesicular membrane causing cell death and releasing amyloid structures into the extracellular space \[[@B42]\].

The contribution of intracellular A*β* to formation of NFTs has also been proposed. The intracellular pool of A*β* associates with tangles \[[@B43]\], and intracellular A*β* may disrupt the cytoskeleton and initiate the formation of aggregated intracellular Tau protein \[[@B12]\]. Contrary to the concept that intracellular A*β* is linked to NFTs, one report found that intracellular A*β* is not a predictor of extracellular A*β* deposition or neurofibrillary degeneration, although in this study mostly an N-truncated form of A*β* was examined \[[@B14]\].

3. Origin of Intraneuronal A*β* {#sec3}
===============================

Based on the evidence presented above, it is now well accepted that two pools of A*β* exist in the brain: intracellular and extracellular. Both A*β* pools are important, and a dynamic relationship between them exists \[[@B9], [@B44]\].

The intraneuronal pool of A*β* has a double origin: slow production from APP inside the neurons and uptake from the extracellular space. These two mechanisms are quite distinct and are regulated differently. Hence, understanding which pathway, if any, is more relevant to AD pathogenesis may help in the identification of potential targets to treat the disease. There is extensive evidence that indicates the production of A*β*~42~ from APP "in situ" inside the neurons \[[@B23], [@B45]--[@B53]\]. We are not going to discuss this mechanism of intracellular A*β* accumulation, which has been reviewed recently \[[@B9], [@B15]\].

Several studies favor a mechanism that involves uptake of A*β* from the extracellular pool \[[@B13], [@B37], [@B54], [@B55]\]. This mechanism of internalization occurs selectively in neurons at risk in AD as demonstrated using organotypic hippocampal slice cultures in which A*β*~42~ gradually accumulates and is retained intact by field CA1, but not by other subdivisions \[[@B40], [@B56]\]. Moreover, A*β* from the periphery enters the brain if the blood brain barrier is compromised and accumulates in neurons but not in glia \[[@B57]\]. Recent work also favored a mechanism of A*β* uptake from the extracellular pool based on the fact that intracellular A*β* was always accompanied by increased extracellular A*β*, while in subjects without increased extracellular A*β* there was no detection of intracellular A*β* \[[@B10]\].

A*β* uptake from the extracellular space and A*β* generation from APP inside neurons have been linked in what can be considered an autocatalytic vicious cycle or loop. According to this concept, intracellular accumulation of A*β*~42~ causes pronounced upregulation of newly generated A*β*~42~ within neurons. Glabe\'s group has shown that internalization of exogenous A*β*~42~ by HEK-293 cells overexpressing APP resulted in accumulation of amyloidogenic fragments of APP \[[@B58]\]. The effect was specific since the amount of nonamyloidogenic *α*-secretase carboxy-terminal fragments was only slightly affected. The accumulation of the amyloidogenic fragments did not result from an increase in APP synthesis, but instead it was due to specific enhancement of peptides stability, possibly by interaction of the fragments with stable A*β* aggregates causing evasion of the normal degradation pathway. Glabe\'s group also demonstrated that the amyloidogenic fragments can be further cleaved to produce A*β*, further supporting the hypothesis that amyloid accumulation is a process mechanistically related to prion replication \[[@B41], [@B59]\]. Exogenous A*β*~42~ might initiate the cycle in the multivesicular bodies or lysosomes, where A*β*~42~ accumulates \[[@B40], [@B58]\]. The induction of amyloidogenic APP fragments by A*β*~42~ was also documented in the field CA1 of hippocampal slices \[[@B40]\], and the accumulation of intracellular A*β* upon A*β*~42~ uptake was demonstrated in dendrites of primary neurons \[[@B60]\]. Importantly, the A*β*-induced synaptic alterations demonstrated in this last study required amyloidogenic processing of APP. Indeed, the decrease in synaptic proteins caused by extracellular A*β* \[[@B32], [@B61]\] is reversed when A*β* is provided together with a *γ*-secretase inhibitor or given to APP knockout neurons \[[@B60]\]. A link between extracellular A*β*-induced neuronal death and APP cleavage has been suggested \[[@B60]\] based on the evidence that extracellular A*β* causes death of wild type neurons but not APP-knock out neurons \[[@B62]\] and that point mutations in the NPXY motif in the C-terminus of APP block A*β* toxicity \[[@B63]\].

4. A*β* Uptake by Neurons {#sec4}
=========================

The molecular events involved in neuronal A*β* internalization in AD are unclear. A*β* is internalized by dissociated neurons, neuron-like cells, and other cells in culture \[[@B64]--[@B71]\] (Song, Baker, Todd, and Kar, resubmitted for publication) and in cultured hippocampal slices \[[@B40], [@B56], [@B72]\]. In neurons, as in other cells, several forms of endocytosis exist (reviewed in \[[@B73]--[@B75]\]). Clathrin-mediated endocytosis has been considered the major mechanism of A*β* internalization until recently but many other endocytic processes independent of clathrin may mediate A*β* uptake.

4.1. Uptake of A*β* through ApoE Receptors {#sec4.1}
------------------------------------------

The first discovered mechanism of clathrin-mediated A*β* endocytosis involved receptors that bind to apolipoprotein E (apoE) and belong to the Low-Density Lipoprotein Receptor (LDLR) family. ApoE is a polymorphic protein that transports extracellular cholesterol. We \[[@B76]\] and others \[[@B77]\] have reviewed the role of apoE in AD, including the increased risk of developing AD in individuals who express the apoE4 isoform. ApoE receptors themselves play important roles in processes related to AD such as neuronal signaling, APP trafficking, and A*β* production (reviewed in \[[@B78]\]).

Studies in human brain indicated that intracellular A*β* accumulation in damaged cells correlates with apoE uptake \[[@B54]\], and neurons with marked intracellular A*β*~42~ immunoreactivity also stain positively for apoE \[[@B12]\]. Furthermore, the presence of one or two apoE4 alleles strongly correlates with an increased accumulation of intraneuronal A*β* \[[@B79]\]. The finding of apoE inside neurons has been taken as evidence of receptor-mediated uptake \[[@B80], [@B81]\]. In support of this concept, intraneuronal A*β* is significantly decreased in brains of PDAPP mice lacking apoE \[[@B82]\].

From the several receptors that belong to the LDLR family and bind apoE, the evidence available points at the low-density lipoprotein receptor-related protein 1 (LRP1) as the most important in A*β* uptake. LRP1 is required for A*β* endocytosis in several cell types including cortical neurons from Tg2576 mice \[[@B67]\], glioblastoma \[[@B68]\] and neuroblastoma cells \[[@B83]\], fibroblasts \[[@B72]\], human cerebrovascular cells \[[@B69]\], synaptosomes and dorsal root ganglion cells \[[@B84]\], and brain endothelial cell lines \[[@B85]\]. Moreover, overexpression of the LRP minireceptor mLRP2 enhanced A*β* uptake in PC12 cells \[[@B82]\], and increased extracellular deposition of A*β* (which was considered as indication of reduced internalization, although this is questionable) was detected in mice that have reduced levels of LRP1 due to deficiency of the chaperone receptor-associated protein (RAP) \[[@B83]\].

Binding of apoE to A*β* increases or decreases A*β* endocytosis depending on the cell type and other environmental conditions \[[@B84]--[@B90]\]. ApoE4, in particular, seems to cause a switch to a mechanism independent of LRP1, mediated by other receptors, which in the blood-brain barrier seems to be VLDLR \[[@B85], [@B87]\]. Whether the formation of a complex A*β*-apoE is required for the regulation of A*β* uptake is still unclear. Some studies showed evidence that LRP1 binds and mediates A*β* endocytosis directly (reviewed in \[[@B78], [@B91]\]), thus apoE would not be required. However, Yamada and colleagues found that A*β* does not interact directly with LRP1 and suggested that a coreceptor might be needed for A*β* internalization \[[@B85]\]. A fragment of apoE increased A*β* uptake without binding A*β* directly or without inducing up-regulation of LRP1 \[[@B92]\]. As apoE, *α*2-macroglobulin (*α*2M) has been linked to AD and is a ligand of LRP1. *α*2M promotes A*β* uptake by cortical neurons \[[@B67]\] and fibroblasts \[[@B72]\] in culture.

4.2. Uptake of A*β* in the Absence of ApoE {#sec4.2}
------------------------------------------

We have speculated that A*β* would exist in the brain in equilibrium between a complex with apoE (or other chaperones) and free A*β* ([Figure 1](#fig1){ref-type="fig"}). That equilibrium would be affected by the affinity of apoE for A*β*, which is isoform specific. In addition, during AD, especially when soluble A*β* accumulates in the brain parenchyma, the pool of free A*β* would increase. We demonstrated that neurons are able to internalize free A*β* in the absence of apoE \[[@B66]\]. ApoE-free A*β* is endocytosed by a mechanism that does not involve receptors of the LDLR family, since it is insensitive to RAP. Interestingly a similar RAP-independent A*β* uptake mechanism has been previously observed in synaptosomes, although it was interpreted as nonspecific internalization by constitutive membrane endocytosis \[[@B84]\]. In our case however, it occurs selectively in neuronal axons and, albeit it is independent of clathrin it requires dynamin suggesting that it is a regulated mechanism of endocytosis. A common form of clathrin-independent endocytosis that requires dynamin also involves caveolae, but in our studies we found that A*β* endocytosis does not require caveolin \[[@B66]\]. We reached this conclusion not because neurons do not express caveolin, in fact the neurons used in our studies (except those isolated from caveolin null mice) do express caveolin, as demonstrated for many other neurons \[[@B93]\], but neurons seem to lack caveolae. N2A cells internalize A*β* by another clathrin-independent, dynamin-mediated endocytosis that requires RhoA \[[@B65]\] suggesting that A*β* might also use the pathway of the IL2R*β* receptor \[[@B74]\].

4.3. Lipids and A*β* Endocytosis {#sec4.3}
--------------------------------

Our work implied that at least one mechanism by which neurons internalize apoE-free A*β* involves noncaveolae, GM1-containing rafts \[[@B66]\]. Lipid raft endocytosis occurs in cells with and without caveolae \[[@B94]\]. A*β* uptake by this mechanism is impaired by the simultaneous inhibition of cholesterol and sphingolipid synthesis, and, under these conditions, there is also decreased uptake of cholera toxin subunit B (CTxB). CTxB binds specifically to the ganglioside GM1 and is a known marker for clathrin-independent endocytosis in many cells \[[@B73]\]. Raft-mediated endocytosis is regulated by plasma membrane cholesterol and sphingolipid. Cholesterol regulates several processes that take place in AD including APP cleavage, A*β* production and/or aggregation, and intracellular APP trafficking \[[@B95], [@B96]\]. Likewise, sphingolipids and gangliosides participate in key events that involve A*β* \[[@B96], [@B97]\]. Previous work demonstrated that the level of cholesterol at the cell surface regulates A*β* binding and A*β* toxicity \[[@B98]--[@B100]\]. None of these studies investigated the role of cholesterol in A*β* internalization. The inhibition of A*β* uptake under low cholesterol and sphingolipid levels could be explained by the disorganization of lipid rafts with the consequent misslocalization of a putative A*β* receptor. Alternatively, A*β* could be internalized in a complex with GM1. Our studies support this last possibility for two reasons; internalized A*β* partially colocalizes with CTxB, and treatment with fumonisin B1 causes decrease of GM1 synthesis \[[@B101]\] and blocks A*β* endocytosis \[[@B66]\]. Our results argue for a concerted role of sphingolipids/gangliosides which is in agreement with extensive evidence and with the model proposed by Dr. Yanagisawa\'s group \[[@B97]\].

4.4. Nicotinic Acetylcholine Receptors {#sec4.4}
--------------------------------------

Other receptors implicated in A*β* internalization are the nicotinic acetylcholine receptors (nAChRs), which have been linked to AD in several other ways (reviewed in \[[@B102], [@B103]\]). The most vulnerable neurons in AD appear to be those that abundantly express nAChRs, particularly neurons of the hippocampus and cholinergic projection neurons from the basal forebrain that express the *α*7nAChR. *α*7nAChR colocalizes with amyloid plaques and more importantly, *α*7nAChR regulates calcium homeostasis and acetylcholine release, two key events in cognition and memory. In addition, *α*7nAChR seems to mediate at least some of the toxic effects of A*β* and A*β*-induced tau phosphorylation.

nAChRs seem to be internalized by endocytosis independent of clathrin and dynamin, in a process that requires the polymerization of actin through activation of Rac-1 \[[@B104]\]. Several studies have suggested the involvement of *α*7nAchR in the internalization of A*β*~42~. Work in brains from patients with AD and in neuroblastoma cells expressing *α*7nAChR suggested that A*β*~42~ accumulates selectively in neurons that express this receptor as the result of internalization of the A*β* in a complex with *α*7nAChR \[[@B55]\]. It is unclear if the role of *α*7nAChR on A*β* uptake depends on the direct binding of A*β* to the nAChR, although A*β* interacts with *α*7nAChR with high affinity \[[@B105], [@B106]\]. S 24795, a novel selective *α*7nAChR partial agonist decreases the interaction between A*β* and *α*7nAChR in vitro and reduces the intraneuronal A*β* load in organotypic frontal cortical slices \[[@B107]\]. However, in our studies using cultured primary rat neurons, A*β*~42~ was unable to compete with *α*-BTx nicotinic receptor binding sites in neuronal membranes, and *α*-BTx did not affect A*β*~42~ internalization, despite the expression of *α*7nAChR, especially in the axons of these neurons \[[@B66]\]. Our results are in agreement with evidence obtained using three different systems namely membrane preparations from rat hippocampus, brain slices and neuroblastoma cells expressing *α*7nAChR \[[@B108]\]. The difference in the results may be explained by the use of different A*β* preparations and the presence or absence of lipoproteins (and therefore A*β* chaperones) in the different studies. Recently, it was shown that the loss of *α*7nAChR in Tg2576 mice (A7KO-APP mice) enhances A*β* oligomer accumulation in the extracellular space and increases early cognitive decline and septohippocampal pathology in young animals \[[@B109]\], but improves cognitive deficits and synaptic pathology in aged A7KO-APP mice \[[@B110]\]. It would be interesting to assess the intraneuronal levels of A*β* in the brain of those animals at different ages.

4.5. Integrins and NMDA Receptors {#sec4.5}
---------------------------------

Two receptors present in many synapses are integrins and N-methyl-D-aspartate (NMDA) receptors. Both receptors regulate clathrin-mediated endocytosis. Several links between A*β* and NMDA receptors have been reported. A*β*-induced neurodegeneration \[[@B111], [@B112]\], disruption of axonal transport \[[@B113]\], and impairment of synaptic transmission \[[@B61]\] are mediated, at least in part, by NMDA receptors. In agreement, neurons are protected against neuronal degeneration and A*β* toxicity by transient inactivation of NMDA receptors \[[@B114], [@B115]\]. Memantine is a noncompetitive NMDA receptor antagonist used for the treatment of moderate to severe AD patients. Memantine protects against neuronal degeneration and A*β* toxicity \[[@B111], [@B116]\]. Importantly, new evidence from Kar\'s laboratory indicated that the protective role of memantine in cultured cortical neurons are independent of endocytosis since memantine was unable to inhibit A*β* uptake (Song, Baker, Todd, and Kar, resubmitted for publication). In other systems, however, the uptake and the effects of A*β*~42~ on hippocampal neurons were blocked by the NMDA receptor antagonist APV \[[@B56]\]. Moreover, it has been reported that A*β* mediates and promotes NMDA receptor endocytosis possibly via the *α*7nAChR \[[@B61], [@B117]\].

The uptake of A*β* by neurons in hippocampal slices is also regulated by integrins. Bi and colleagues found that integrin antagonists enhance A*β* uptake \[[@B56]\]. They propose the following mechanisms of action for integrin antagonists: (i) the increase in peptide availability for uptake, due to disruption of the interaction of A*β* with integrins, which might represent the first step in A*β* extracellular proteolysis, (ii) the facilitation of endocytosis, by reducing the binding of integrins to the extracellular matrix and submembrane cytoskeleton which would slow invagination and endocytosis and (iii) a change in lysosomal proteolysis of A*β* since adhesion receptors can change the rate at which primary lysosomes are formed. Moreover, they suggested that the selectivity in A*β* uptake could be explained by the different types of integrin subunits expressed in each area of the brain or even in specific neurons.

4.6. Receptor for Advanced Glycation End Products (RAGEs) {#sec4.6}
---------------------------------------------------------

The receptor for advanced glycation end products (RAGEs) is considered a primary transporter of A*β* across the blood-brain barrier into the brain from the systemic circulation \[[@B118]\], but some evidence exists that RAGE binds monomeric, oligomeric, and even fibrillar A*β* at the surface of neurons \[[@B119]--[@B121]\]. Recently, it was reported that RAGE cointernalizes with A*β* and colocalizes with A*β* at the hippocampus of mouse model of AD and that blockade of RAGE decreases A*β* uptake and A*β* toxicity \[[@B122]\].

5. Consequences of Intraneuronal Accumulation of A*β* {#sec5}
=====================================================

The cellular uptake and degradation of A*β* have been originally considered as mechanisms that reduce the concentration of A*β* in interstitial fluids. However, A*β*~42~ is degraded poorly, and its accumulation inside neurons has dramatic consequences. Intraneuronal A*β* accumulates within the endosomal/lysosomal system, in vesicles sometimes identified as lysosomes \[[@B13], [@B40], [@B56], [@B64], [@B71], [@B82], [@B123]\] and some others as late endosomes/multivesicular bodies (MVBs) \[[@B30], [@B124]--[@B126]\]. In sympathetic neurons we found that A*β*~42~ causes sequestration of cholesterol ([Figure 2(a)](#fig2){ref-type="fig"}), which colocalizes with LAMP-1 and is the site of A*β* accumulation ([Figure 2(b)](#fig2){ref-type="fig"}).

A*β*~42~ internalized from the extracellular milieu is quite resistant to degradation possibly due to formation of protease resistant aggregates. Shorter A*β* peptides are degraded and do not accumulate after endocytosis \[[@B58], [@B59], [@B123], [@B127]\]. In one study A*β*~42~ was shown to be cleared rapidly after delivery to lysosomes, although it previously concentrated and aggregated within the cells, possibly serving as a seed for further A*β* aggregation \[[@B71]\].

A*β* accumulation in lysosomes may cause loss of lysosomal membrane impermeability and leakage of lysosomal content (proteases and cathepsins) causing apoptosis and necrosis \[[@B13], [@B55], [@B123], [@B128]--[@B130]\] (Song, Baker, Todd, and Kar, resubmitted for publication). The release of lysosomal contents into the cytoplasmic compartments has been considered one of the earliest events in intracellular A*β*-mediated neurotoxicity in vitro \[[@B123]\], and inhibition of lysosomal enzymes protects against A*β* toxicity in cultured cells \[[@B131]\]. ApoE4 potentiates A*β*-induced lysosomal leakage and apoptosis in N2A cells by a mechanism that requires endocytosis by LRP1 \[[@B132]\]. Immunogold studies suggested that the disruption of MVBs could release enough A*β*~42~ to induce neurotoxicity \[[@B30]\].

An increase in cathepsin D levels secondary to A*β* internalization has been reported in hippocampal slices \[[@B56], [@B133]\] and cultured cortical neurons (Song, Baker, Todd, and Kar, resubmitted for publication). Elevation of cathepsin D levels is a characteristic of AD brains \[[@B134]--[@B136]\]; endosome dysfunction occurs early in AD, before amyloid deposition (reviewed in \[[@B128]\]) and is enhanced in persons expressing apoE4 \[[@B137]\]. Abnormal endosomes are also detected in Down syndrome and Niemann-Pick type C, in which A*β* peptide accumulates intracellularly \[[@B138]\].

Endosomal dysfunction, however, might not necessarily involve lysosomal leakage in all cases but could involve defects in intracellular trafficking. MVBs are considered late endosomes, which form by fusion of early endosomes with signaling endosomes and serve as vehicle for the transport of receptors and signaling molecules \[[@B139]\]. MVBs are important vesicles in retrograde transport, and accumulation of A*β* within MVBs would impair their degradative and trafficking functions. MVBs contain inner vesicles with lower pH in the lumen. A*β* interacts with, and partitions into negatively charged membranes \[[@B140]\] and there is evidence that A*β*~42~ is localized to the outer membrane of the MVBs in brains of patients with AD \[[@B30]\], and is inserted in the membrane of lysosomes in cultured cells that internalized A*β* \[[@B130]\]. The MVBs represent a good location for A*β* aggregation because MVBs are rich in membranes and have low pH \[[@B30]\]. In addition, A*β* accumulation in MVBs membranes will likely disrupt intracellular trafficking as mentioned above.

In neurons, axonal retrograde transport is essential for neuronal life since it secures the delivery of growth factors and/or their survival signals to the soma. This requires the normal function of the endosomal system in axons \[[@B141], [@B142]\] and will likely be affected by A*β* accumulation in axonal MVBs. We demonstrated that axons are entry points of A*β* and apoE \[[@B66], [@B143]\] suggesting that accumulation of A*β* in axonal MVBs could impair retrograde transport. Our new evidence suggests that cholesterol accumulation in MVBs could worsen intracellular trafficking in neurons. The impairment of retrograde transport has been proposed to play an important role in degeneration of basal forebrain cholinergic neurons in AD \[[@B144], [@B145]\]. Recent work has shown impairment of BDNF-mediated TrkB retrograde transport in Tg2576 axons and in cultured neurons treated with A*β* \[[@B146]\].

Protein sorting into MVBs is a highly regulated event. One of the mechanisms of MVB sorting is the ubiquitin proteasome system (UPS) \[[@B147]\]. A*β* inhibits the proteasome \[[@B148]--[@B150]\]. Important in the context of this review, part of A*β* internalized by neurons appears in the cytosol, where it could get in contact with the proteasome \[[@B149]\]. LaFerla\'s group demonstrated an age-dependent proteasome inhibition in the triple transgenic mice model of AD \[[@B150]\]. This inhibition was responsible for tau phosphorylation and was reversed by A*β* immunotherapy. Inhibition of the UPS was responsible for impairment of the MVB sorting pathway in cultured Tg2576 neurons challenged with A*β* \[[@B124]\]. Inhibition of fast axonal transport by A*β* by mechanisms that do not involve MVBs directly has also been reported \[[@B151]\].

6. Neuronal Death Secondary to A*β* Uptake {#sec6}
==========================================

The role of A*β* in neuronal death and dysfunction has been investigated extensively. The attention has focused mainly on how extracellular A*β* causes neuronal death. On the other hand, whether the intracellular accumulation of A*β* is a cause of neuronal death has been a matter of debate. Some groups consider that intracellular accumulation of A*β* is not responsible for neuronal loss. For instance, the appearance of A*β* immunoreactivity in neurons in infants and during late childhood, adulthood, and normal aging, suggests that this is part of the normal neuronal metabolism \[[@B14]\]. Moreover, A*β* did not produce clear signs of cell death upon infusion in hippocampal slices \[[@B40]\] although in combination with transforming growth factor-*β* (TGF-*β*) it induced neuronal degeneration in field CA1 \[[@B152]\]. On the other hand, evidence that supports the importance of intracellular A*β* in cell death includes the observations that different mice models of AD show dramatic intraneuronal A*β* accumulation and neuronal cell death that correlates with intraneuronal A*β* accumulation and precedes A*β* deposition \[[@B7], [@B26], [@B29], [@B55], [@B126], [@B153]\]. Moreover, the abnormalities and cognitive dysfunctions in several models of AD correlate with the appearance of intraneuronal A*β*, before the appearance of plaques or tangles \[[@B18], [@B19]\]; markers of apoptosis are present in the subset of neurons that accumulate A*β* in Down syndrome brains \[[@B25]\], and microinjections of A*β*~42~ or a cDNA-expressing cytosolic A*β*~42~ rapidly induces cell death of primary human neurons \[[@B27]\]. In addition, treatment of cultured neurons or neuron-like cells with A*β*~42~ causes A*β* internalization and death \[[@B55], [@B65], [@B66], [@B116], [@B123], [@B154], [@B155]\] (Song, Baker, Todd, and Kar, resubmitted for publication).

The evidence above opens the question whether A*β* internalization is required for toxicity. Inhibition of A*β* endocytosis in N2A cells \[[@B65]\], primary cortical neurons (Song, Baker, Todd, and Kar, resubmitted for publication) and sympathetic neurons (Saavedra and Posse de Chaves, unpublished observations) resulted in significantly less intracellular A*β* accumulation and reduced A*β* toxicity. Besides, the selective toxicity of A*β* oligomers versus A*β* fibrils has been explained by the preferential oligomeric A*β* uptake by receptor-mediated endocytosis \[[@B156]\]. As indicated above, the endocytic mechanisms used by A*β* in different cells or under different conditions seem to be different, but in all cases the fate of internalized A*β* is similar, being delivered to MVBs or lysosomes.

7. A*β* Internalization by Astrocytes and Microglia {#sec7}
===================================================

The accumulation of activated astrocytes and microglia close to A*β* deposits suggests that these cells play a role in AD pathology \[[@B157]--[@B159]\]. Astrocytes are the most abundant type of cells in the CNS. Upon exposure to A*β*, they become activated and play a neuroprotective role by extending their hypertrophic processes to physically separate the neurons from A*β* fibrils \[[@B160]\]. In addition, activated astrocytes can internalize and degrade A*β* \[[@B161]\], possibly in an attempt to reduce A*β* availability to neurons. Nevertheless, exposure of astrocytes to A*β* could have detrimental consequences. A*β* upregulates inflammatory cytokines and increases the release of nitric oxide in cultured astrocytes \[[@B162]\]. Moreover, A*β* induces not only astrocytic cell death \[[@B163]\], but also neuronal cell death indirectly \[[@B164]\].

Microglia are mononuclear phagocytes of the innate immune system in the CNS. MicrogIia can act as a dual sword in AD pathology. A*β* deposition activates microglia, which release proinflammatory cytokines and other cytotoxic compounds that cause neurodegeneration \[[@B165], [@B166]\]. Some studies, however, suggested a neuroprotective role of microglia via their ability to internalize and degrade A*β* \[[@B167]--[@B170]\].

The evidence of A*β* accumulation in brain glia in AD is contentious. A*β* accumulation in areas with high A*β* deposition has been shown in astrocytes and microglia \[[@B171]\] or astrocytes but not microglia or neurons \[[@B172], [@B173]\]. Blood-derived A*β*~42~ is able to cross a compromised blood-brain barrier, is internalized, and accumulates in cortical pyramidal neurons but not in glia \[[@B57]\]. But continuous intracerebral infusion of A*β* in rat brain resulted in A*β* accumulation in astrocytes but not microglia \[[@B174]\]. The lack of intracellular A*β* in microglia cannot be interpreted as microglia being unable to take up A*β*, since it could also reflect that they are highly efficient in degrading it \[[@B174]\]. A theory that opposes this concept establishes that, instead of accumulating A*β* intracellularly, microglia release fibril A*β* contributing to the growth of amyloid plaques \[[@B160], [@B175]\]. A*β* internalization by microglia in vitro has been shown in several studies \[[@B176], [@B177]\]. 3D reconstruction of ultrathin sectioning of microglia cells in the vicinity of dense-core amyloid plaque showed that amyloid plaques were exclusively extracellular deposits suggesting that microglia do not internalize fibril A*β* \[[@B178]\]. On the contrary, Bolmont et al. found that plaque-associated microglia internalize a fluorescent dye binding amyloid injected systemically. The intracellular dye particles were positive for A*β* and were not continuous with the amyloid plaque, suggesting true A*β* internalization by microglia \[[@B179]\].

As discussed for neurons, the intracellular pool of A*β* in microglia and astrocytes could be derived from increased endogenous production or increased internalization of exogenous A*β*. Some studies showed that A*β* production in these cells is very low due to reduced APP expression in microglia and reduced beta-secretase activity in astrocytes compared to neurons \[[@B180]--[@B182]\]. Nevertheless some stimuli induce expression of APP, beta-secretase, *γ*-secretase and production of A*β* in astrocytes and microglia \[[@B183]--[@B185]\].

7.1. A*β* Internalization by Astrocytes {#sec7.1}
---------------------------------------

The involvement of LDLR/LRP1 in A*β* internalization by astrocytes is controversial. The ability of astrocytes to degrade A*β* deposits demonstrated in brains of transgenic PDAPP mice depends on apoE secretion and is blocked by RAP suggesting a mechanism mediated by a member of the LDLR family \[[@B186]\]. Unfortunately, A*β* internalization by astrocytes was not examined in this study \[[@B186]\], and in view that A*β* degradation by astrocytes could be mediated by extracellular matrix metalloproteinases \[[@B187]\], A*β* internalization in this paradigm is not granted. One study showed that A*β*-induced activation of cultured astrocytes is mediated by LRP \[[@B188]\] suggesting that LRP participates in A*β* uptake, although A*β* internalization was not directly examined under these conditions either. Conversely, another study demonstrated that A*β* internalization by astrocytes is not affected by RAP treatment \[[@B69]\] arguing against the involvement of LDLR/LRP1.

The accumulation of fibrillar A*β* in cytoplasmic vesicles of human astrocytes is associated with increased cellular level of apoJ/clusterin \[[@B189]\]. Since apoJ/clusterin binds to fibrillar A*β* \[[@B190]\] and is involved in LRP1- and scavenger-receptor-mediated endocytosis/phagocytosis \[[@B191]\], it was hypothesized that human astrocytes can take up fibril A*β* via apoJ/clusterin-mediated endocytosis \[[@B189]\]. Recently, it has been shown that astrocytes can take up oligomeric A*β* better than fibrillar A*β* \[[@B192]\]. ApoE and apoJ/clusterin reduced oligomeric A*β* positive astrocytes without affecting fibril A*β* uptake \[[@B192]\]. This indicates that A*β* uptake by astrocytes depends on A*β* aggregation status and that oligomeric A*β* internalization by astrocytes could be mediated by the LDLR family.

Scavenger receptors (SRs) are cell surface receptors expressed by diverse cell types that bind to a variety of unrelated ligands \[[@B193]\]. Based on the ability of fucoidan and polyinosinic acid, known ligands for SR, to reduce A*β* binding to and internalization by astrocytes SRs have been recognized as possible mediators of A*β* internalization by astrocytes \[[@B164], [@B194], [@B195]\].

Formyl peptide receptor-like 1 (FPRL1) is a G protein-coupled receptor regulating the immune responses \[[@B196]\]. FPRL1 mediates A*β* internalization in astrocytes. Immunostaining of A*β*-treated astrocytes shows colocalization of internalized A*β* and FPRL1. In addition, cotreatment with a FPRL1 agonist (fMLF) or antagonist (WRW4) reduces A*β* internalization. This indicates that A*β* binds to FPRL1 stimulating the complex internalization \[[@B197]\].

Another type of receptors that has shown to be involved in A*β* internalization by astrocytes is leucine-rich glioma inactivated protein 3 (LGI3), a type I transmembrane protein containing leucine rich repeat (LRR) \[[@B198], [@B199]\]. A*β* induces the expression of the Lib gene in astrocytes, which encodes for LRR-containing type I transmembrane proteins \[[@B200]\]. These LRR containing proteins are thought to mediate protein-protein or protein-matrix interactions \[[@B201]\]. LGI3 colocalizes with A*β* at the plasma membrane and intracellularly in astrocytes suggesting that LGI3 could be playing a role in A*β* internalization \[[@B198]\]. This was supported by the ability of LGI3 downregulation to reduce A*β* internalization by astrocytes \[[@B199]\]. LGI3 is involved in clathrin-mediated endocytosis in astrocytes and neuronal cell lines \[[@B199]\]. It interacts with flotillin regulating APP intracellular trafficking in neuronal cells \[[@B202]\].

Phagocytosis is another mechanism that could mediate A*β* internalization by astrocytes. Astrocytes that accumulate A*β* in AD brains also have high levels of neuron-specific choline acetyltransferase (ChAT) and *α*7nAChR \[[@B163]\], which suggest that astrocytes are able to internalize A*β*-loaded neurons via phagocytosis. However, the evidence that cytochalasin B, an inhibitor of phagocytosis, does not block A*β* internalization in astrocytes is in conflict with this notion \[[@B203]\].

7.2. A*β* Internalization by Microglia {#sec7.2}
--------------------------------------

With respect to the mechanisms that mediate A*β* uptake in microglia, the evidence suggest that different mechanisms exist for soluble and aggregated A*β* (reviewed in \[[@B204]\]). Soluble A*β* internalization by microglia does not depend on the presence of apoE \[[@B205]\] and is not blocked by RAP treatment \[[@B168], [@B170]\] excluding the involvement of LDLR/LRP-1. Internalized soluble A*β* does not colocalize with internalized transferrin further excluding clathrin-mediated endocytosis \[[@B168]\]. Moreover, soluble A*β* internalization by microglia is nonsaturable excluding receptor-mediated internalization \[[@B168], [@B170]\]. Soluble A*β* internalization by microglia has been classified as fluid phase macropinocytosis, a process dependent on cytoskeletal structures. A*β*-containing macropinocytic vesicles fuse with late endosomes and later with lysosomes, where they are degraded \[[@B168]\]. Blocking microglial surface receptors that mediate fibril A*β* internalization do not affect internalization of soluble A*β* \[[@B168]\] confirming that the two mechanisms are different.

Fibril/aggregated A*β* internalization by microglia seems to proceed by receptor-mediated endocytosis and receptor-mediated phagocytosis \[[@B177], [@B206]\]. The surface receptors involved are Pattern Recognition Receptors (PRRs). These are the receptors used by the innate immune system to recognize pathogen associated molecular pattern, including SR-type A, CD14, CD47, SR-type B (CD36), *α*6*β*1 integrin, and toll-like receptors (TLRs) \[[@B177], [@B206]--[@B211]\]. Microglia take up fibril A*β* into phagosomes, which then enter the endosomal-lysosomal system for degradation \[[@B177], [@B206], [@B207]\]. Fibril A*β* internalization by microglia is blocked by the scavenger receptor agonists Ac-LDL or fucoidan, but not by RAP indicating the involvement of scavenger receptors but not LDLR/LPR-1 \[[@B177]\]. Microglia that do not express CD14 have lower ability to take up A*β* \[[@B207]\]. The microglial A*β* cell surface receptor complex, composed of *α*6*β*1 integrin, CD47 (integrin-associated protein), and the B-class scavenger receptor CD36 \[[@B210]\], mediates microglial uptake of fibril A*β* via a receptor mediated nonclassical phagocytosis \[[@B206]\]. Activation of toll-Like Receptors (TLRs) increases microglial ability to internalize A*β* \[[@B207]--[@B209], [@B212]\]. TLRs activation increases the expression of G protein-coupled mouse formyl peptide receptor 2 (mFPR2), mouse homologue of FPRL1, in microglia. Increased A*β* uptake by microglia upon TLRs activation was blocked by pertussis toxin PTX, G*α*i-protein coupled receptor deactivator, W peptide, mFPR2 agonist, anti-CD14, as well as scavenger receptors ligand. This indicates that mFPR2, CD14 and scavenger receptors work together to increase A*β* internalization by microglia upon TLR activation \[[@B208], [@B209]\]. In addition, formyl peptide receptor-like 1 (FPRL1) was also found to mediate A*β* internalization in microglia \[[@B197]\].

In addition, microglia can internalize fibril A*β* by phagocytosis stimulated by A*β*-antibody complex interaction with Fc-receptor \[[@B177], [@B213]\] and/or fibril A*β* interaction with the complement system C1q (antibody dependent) or C3b (antibody independent) \[[@B204], [@B214]--[@B216]\].

8. Conclusions {#sec8}
==============

The intracellular accumulation of A*β* has been confirmed, and evidence of A*β* internalization from outside the cells exist. Neurons seem to use different mechanisms than glia to take up A*β*. The existence of phagocytic processes in glia suggests that these cells participate mostly in the clearance of A*β*. More research is required to understand if neurons take up A*β* under physiological conditions and whether this is part of A*β* normal metabolism. Regulated endocytosis is the main process by which neurons internalize A*β*. The participation of a number of receptors suggests that more than one mechanism exists. The challenge ahead is to understand the significance of this diversity in the development and progression of AD.
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![Mechanisms of A*β* internalization in neurons and glia.](IJAD2011-127984.001){#fig1}

![A*β* causes cholesterol sequestration in primary neurons. (a) Rat primary neurons (forebrain and sympathetic) cultured in serum-free medium, were treated for 24 h with 20 *μ*M oligomeric A*β*~42~ (prepared according to \[[@B66]\]) or with 1.5 *μ*M U18666A, a drug extensively used to induce cholesterol sequestration. Cholesterol was examined by confocal microscopy, using filipin. (b) Neurons were treated as in (a) but fluorescent oligomeric A*β*~42~ was used. Intracellular localization of cholesterol and A*β* was examined by double indirect immunofluorescence confocal microscopy using LAMP1 as a marker of late endosome/MVBs and EEA1 as a marker of early endosomes.](IJAD2011-127984.002){#fig2}
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